Looking beyond the spin of Big Pharma PR. But encouraging gossip. Come in and confide, you know you want to! “I’ll publish right or wrong. Fools are my theme, let satire be my song.”
Email: jackfriday2011(at)hotmail.co.uk
In June 2006, CIBC World Markets expected the SAINT II study to enrol ahead of schedule and the companies to report top-line data this year. The analysts believed this study was likely to be successful based on NXY-059's demonstrations in the SAINT I study .
In February 2006, commenting on the publication of the full data set from the SAINT-I trial, analysts at Dresdner Kleinwort Wasserstein stated that, like interim data from the study, the findings showed improvement in the modified Rankin scale (mRS)but no improvement in neurological functioning as measured by NIH Stroke Scale (NIHSS). They also believed that data from the ongoing CHANT trial, due later in 2006, would not be pivotal in terms of efficacy. Dresdner Kleinwort sees data from the ongoing SAINT-II trial (due early in 2007) as key to determining disufenton's potential. The analysts believe that the drug remains high risk, but if (and they believe it is a 'big if') it can show repeated efficacy, it could earn in excess of $1 billion. Analysts at CIBC World Markets believed that SAINT-II data are likely to be positive on the mRS primary endpoint, and may well reach the NIHSS endpoint, in light of the trial's expansion. CIBC also consider disufenton to have a positive risk/benefit profile, given the moderate efficacy and clean safety results published previously
1 comment:
In June 2006, CIBC World Markets expected the SAINT II study to enrol ahead of schedule and the companies to report top-line data this year. The analysts believed this study was likely to be successful based on NXY-059's demonstrations in the SAINT I study .
In February 2006, commenting on the publication of the full data set from the SAINT-I trial, analysts at Dresdner Kleinwort Wasserstein stated that, like interim data from the study, the findings showed improvement in the modified Rankin scale (mRS) but no improvement in neurological functioning as measured by NIH Stroke Scale (NIHSS). They also believed that data from the ongoing CHANT trial, due later in 2006, would not be pivotal in terms of efficacy. Dresdner Kleinwort sees data from the ongoing SAINT-II trial (due early in 2007) as key to determining disufenton's potential. The analysts believe that the drug remains high risk, but if (and they believe it is a 'big if') it can show repeated efficacy, it could earn in excess of $1 billion. Analysts at CIBC World Markets believed that SAINT-II data are likely to be positive on the mRS primary endpoint, and may well reach the NIHSS endpoint, in light of the trial's expansion. CIBC also consider disufenton to have a positive risk/benefit profile, given the moderate efficacy and clean safety results published previously
Post a Comment